Table 2 Efficacy of hepatitis C treatment with pegylated interferon (PEG‐IFN) plus ribavirin.

Study	Treatment	HCV genotype	Duration (weeks)	SVR (%)
Manns16	1.5 μg/kg PEG‐IFN alpha‐2b	HCV‐1	48	42
	800 mg ribavirin	HCV‐2/3	48	82
	1.5 μg/kg PEG‐IFN alpha‐2b	HCV‐1	48	48 (retrospective)
	>10.6 mg/kg ribavirin	HCV‐2/3	48	88 (retrospective)
Fried19	180 μg PEG‐IFN alpha‐2a	HCV‐1	48	46
	1000/1200 mg ribavirin	HCV‐2/3	48	76
Hadziyannis20	180 μg PEG‐IFN alpha‐2a	HCV‐1	24	29
	800 mg ribavirin		48	40
		HCV‐2/3	24	78
			48	73
	180 μg PEG‐IFN alpha‐2a	HCV‐1	24	41
	1000/1200 mg ribavirin		48	51
		HCV‐2/3	24	78
			48	77
Zeuzem24	1.5 μg/kg PEG‐IFN alpha‐2b	HCV‐2	24	93
	800–1400 mg ribavirin	HCV‐3		79
Kamal109	1.5 μg/kg PEG‐IFN alpha‐2b	HCV‐4	24	29
	1000/1200 mg ribavirin		36	66
			48	69
von Wagner27	180 μg PEG‐IFN alpha‐2a	HCV‐2/3	24	36 if TW4 HCV‐RNA ⩾600 IU/ml
	800–1200 mg ribavirin		24	80 if TW4 HCV‐RNA <600 IU/ml
			16	82 if TW4 HCV‐RNA <600 IU/ml
Zeuzem32	1.5 μg/kg PEG‐IFN alpha‐2b	HCV‐1 LVL	24	50
	800–1400 mg ribavirin	(<600 000 IU/ml)		89 if TW4 HCV‐RNA negative (<29 IU/ml)

Sustained virological response rates (SVR) depend on hepatitis C virus (HCV) genotype, dose, and duration of treatment.

TW4, four weeks of therapy.